{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:09:45Z","timestamp":1792631385182,"version":"4.5.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-024-02459-y","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T13:02:47Z","timestamp":1725368567000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Evaluation of three alternative methods to the plaque reduction neutralizing assay for measuring neutralizing antibodies to dengue virus serotype 2"],"prefix":"10.1186","volume":"21","author":[{"given":"Vanessa Shi Li","family":"Goh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Chong Wei","family":"Ang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swee Ling","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei Xuan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin Xiang","family":"Setoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith Chui Ching","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,3]]},"reference":[{"key":"2459_CR1","doi-asserted-by":"crossref","unstructured":"Hempel H et al. The importance of using WHO International standards to harmonise SARS-CoV-2 serological assays. Lancet Microbe, 2024. 5(3).","DOI":"10.1016\/S2666-5247(23)00258-6"},{"issue":"6","key":"2459_CR2","doi-asserted-by":"publisher","first-page":"e1199","DOI":"10.1371\/journal.pntd.0001199","volume":"5","author":"SR Fry","year":"2011","unstructured":"Fry SR, et al. The diagnostic sensitivity of dengue rapid test assays is significantly enhanced by using a combined antigen and antibody testing approach. PLoS Negl Trop Dis. 2011;5(6):e1199.","journal-title":"PLoS Negl Trop Dis"},{"key":"2459_CR3","doi-asserted-by":"crossref","unstructured":"Conklin SE et al. Evaluation of Serological SARS-CoV-2 lateral Flow assays for Rapid Point-of-care testing. J Clin Microbiol, 2021. 59(2).","DOI":"10.1128\/JCM.02020-20"},{"key":"2459_CR4","doi-asserted-by":"publisher","first-page":"103455","DOI":"10.1016\/j.ebiom.2021.103455","volume":"69","author":"I Wagenh\u00e4user","year":"2021","unstructured":"Wagenh\u00e4user I, et al. Clinical performance evaluation of SARS-CoV-2 rapid antigen testing in point of care usage in comparison to RT-qPCR. EBioMedicine. 2021;69:103455.","journal-title":"EBioMedicine"},{"key":"2459_CR5","doi-asserted-by":"publisher","first-page":"852452","DOI":"10.3389\/fimmu.2022.852452","volume":"13","author":"SC Lai","year":"2022","unstructured":"Lai SC, et al. Development of Novel Dengue NS1 Multiplex lateral Flow Immunoassay to differentiate serotypes in serum of Acute Phase patients and infected mosquitoes. Front Immunol. 2022;13:852452.","journal-title":"Front Immunol"},{"key":"2459_CR6","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/1743-422X-10-126","volume":"10","author":"AK Falconar","year":"2013","unstructured":"Falconar AK, Romero-Vivas CM. A simple, inexpensive, robust and sensitive dot-blot assay for equal detection of the nonstructural-1 glycoprotein of all dengue virus serotypes. Virol J. 2013;10:126.","journal-title":"Virol J"},{"key":"2459_CR7","doi-asserted-by":"crossref","unstructured":"Kodani M et al. An automated immunoblot method for detection of IgG antibodies to Hepatitis C Virus: a potential supplemental antibody confirmatory assay. J Clin Microbiol. 2019;57(3).","DOI":"10.1128\/JCM.01567-18"},{"key":"2459_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jviromet.2018.03.007","volume":"257","author":"EJM Nascimento","year":"2018","unstructured":"Nascimento EJM, et al. Development of an anti-dengue NS1 IgG ELISA to evaluate exposure to dengue virus. J Virol Methods. 2018;257:48\u201357.","journal-title":"J Virol Methods"},{"key":"2459_CR9","doi-asserted-by":"crossref","unstructured":"Mishra N et al. Diagnosis of Zika Virus infection by peptide array and enzyme-linked immunosorbent assay. mBio. 2018;9(2).","DOI":"10.1128\/mBio.00095-18"},{"issue":"7","key":"2459_CR10","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.3201\/eid2607.200841","volume":"26","author":"NMA Okba","year":"2020","unstructured":"Okba NMA, et al. Severe Acute Respiratory Syndrome Coronavirus 2-Specific antibody responses in Coronavirus Disease patients. Emerg Infect Dis. 2020;26(7):1478\u201388.","journal-title":"Emerg Infect Dis"},{"issue":"15","key":"2459_CR11","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1093\/cid\/ciaa310","volume":"71","author":"L Guo","year":"2020","unstructured":"Guo L, et al. Profiling early humoral response to diagnose Novel Coronavirus Disease (COVID-19). Clin Infect Dis. 2020;71(15):778\u201385.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2459_CR12","doi-asserted-by":"publisher","first-page":"18000","DOI":"10.1038\/s41598-021-97339-8","volume":"11","author":"KI Matsunaga","year":"2021","unstructured":"Matsunaga KI, et al. Competitive ELISA for a serologic test to detect dengue serotype-specific anti-NS1 IgGs using high-affinity UB-DNA aptamers. Sci Rep. 2021;11(1):18000.","journal-title":"Sci Rep"},{"key":"2459_CR13","doi-asserted-by":"publisher","first-page":"32227","DOI":"10.1038\/srep32227","volume":"6","author":"D Acharya","year":"2016","unstructured":"Acharya D, et al. An ultrasensitive electrogenerated chemiluminescence-based immunoassay for specific detection of Zika virus. Sci Rep. 2016;6:32227.","journal-title":"Sci Rep"},{"key":"2459_CR14","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.cca.2020.09.005","volume":"510","author":"CS Lau","year":"2020","unstructured":"Lau CS, et al. Performance of an automated chemiluminescence SARS-CoV-2 IG-G assay. Clin Chim Acta. 2020;510:760\u20136.","journal-title":"Clin Chim Acta"},{"issue":"5","key":"2459_CR15","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1515\/cclm-2022-0053","volume":"60","author":"G Lippi","year":"2022","unstructured":"Lippi G, Henry BM, Adeli K. Diagnostic performance of the fully automated Roche Elecsys SARS-CoV-2 antigen electrochemiluminescence immunoassay: a pooled analysis. Clin Chem Lab Med. 2022;60(5):655\u201361.","journal-title":"Clin Chem Lab Med"},{"issue":"9","key":"2459_CR16","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.1016\/S1473-3099(20)30517-X","volume":"20","author":"RW Peeling","year":"2020","unstructured":"Peeling RW, et al. Serology testing in the COVID-19 pandemic response. Lancet Infect Dis. 2020;20(9):e245\u20139.","journal-title":"Lancet Infect Dis"},{"key":"2459_CR17","doi-asserted-by":"publisher","first-page":"975398","DOI":"10.3389\/fcimb.2022.975398","volume":"12","author":"KR Chan","year":"2022","unstructured":"Chan KR, et al. Serological cross-reactivity among common flaviviruses. Front Cell Infect Microbiol. 2022;12:975398.","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"2459_CR18","doi-asserted-by":"publisher","first-page":"e0244601","DOI":"10.1371\/journal.pone.0244601","volume":"16","author":"SL Low","year":"2021","unstructured":"Low SL, et al. Evaluation of eight commercial Zika virus IgM and IgG serology assays for diagnostics and research. PLoS ONE. 2021;16(1):e0244601.","journal-title":"PLoS ONE"},{"key":"2459_CR19","volume-title":"Guidelines for plaque reduction neutralization testing of human antibodies to dengue viruses","author":"World Health Organization","year":"2007","unstructured":"World Health Organization. Guidelines for plaque reduction neutralization testing of human antibodies to dengue viruses. World Health Organization: Geneva; 2007."},{"issue":"10249","key":"2459_CR20","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","volume":"396","author":"PM Folegatti","year":"2020","unstructured":"Folegatti PM, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467\u201378.","journal-title":"Lancet"},{"issue":"7","key":"2459_CR21","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/S1473-3099(21)00070-0","volume":"21","author":"R Ella","year":"2021","unstructured":"Ella R, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Dis. 2021;21(7):950\u201361.","journal-title":"Lancet Infect Dis"},{"key":"2459_CR22","doi-asserted-by":"publisher","first-page":"100689","DOI":"10.1016\/j.eclinm.2020.100689","volume":"31","author":"P Tebas","year":"2021","unstructured":"Tebas P, et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label, phase 1 clinical trial. EClinicalMedicine. 2021;31:100689.","journal-title":"EClinicalMedicine"},{"key":"2459_CR23","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.cca.2021.10.028","volume":"523","author":"A Padoan","year":"2021","unstructured":"Padoan A, et al. SARS-CoV-2 neutralizing antibodies after one or two doses of Comirnaty (BNT162b2, BioNTech\/Pfizer): Kinetics and comparison with chemiluminescent assays. Clin Chim Acta. 2021;523:446\u201353.","journal-title":"Clin Chim Acta"},{"issue":"1","key":"2459_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41467-020-20247-4","volume":"12","author":"EHY Lau","year":"2021","unstructured":"Lau EHY, et al. Neutralizing antibody titers in SARS-CoV-2 infections. Nat Commun. 2021;12(1):63.","journal-title":"Nat Commun"},{"issue":"3","key":"2459_CR25","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1515\/cclm-2021-1247","volume":"60","author":"A Padoan","year":"2022","unstructured":"Padoan A, et al. Neutralizing antibody titers six months after Comirnaty vaccination: kinetics and comparison with SARS-CoV-2 immunoassays. Clin Chem Lab Med. 2022;60(3):456\u201363.","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"2459_CR26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.4269\/ajtmh.14-0671","volume":"93","author":"SL Low","year":"2015","unstructured":"Low SL, et al. Dengue seroprevalence of healthy adults in Singapore: serosurvey among blood donors, 2009. Am J Trop Med Hyg. 2015;93(1):40\u20135.","journal-title":"Am J Trop Med Hyg"},{"issue":"6","key":"2459_CR27","doi-asserted-by":"publisher","first-page":"e0006616","DOI":"10.1371\/journal.pntd.0006616","volume":"12","author":"RT Sasmono","year":"2018","unstructured":"Sasmono RT, et al. Dengue virus serotype distribution based on serological evidence in pediatric urban population in Indonesia. PLoS Negl Trop Dis. 2018;12(6):e0006616.","journal-title":"PLoS Negl Trop Dis"},{"issue":"8","key":"2459_CR28","doi-asserted-by":"publisher","first-page":"e1065","DOI":"10.1016\/S2214-109X(19)30250-5","volume":"7","author":"MV Murhekar","year":"2019","unstructured":"Murhekar MV, et al. Burden of dengue infection in India, 2017: a cross-sectional population based serosurvey. Lancet Glob Health. 2019;7(8):e1065\u201373.","journal-title":"Lancet Glob Health"},{"issue":"1","key":"2459_CR29","doi-asserted-by":"publisher","first-page":"e0010021","DOI":"10.1371\/journal.pntd.0010021","volume":"16","author":"K Limkittikul","year":"2022","unstructured":"Limkittikul K, et al. Dengue virus seroprevalence study in Bangphae district, Ratchaburi, Thailand: a cohort study in 2012\u20132015. PLoS Negl Trop Dis. 2022;16(1):e0010021.","journal-title":"PLoS Negl Trop Dis"},{"issue":"7446","key":"2459_CR30","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nature12060","volume":"496","author":"S Bhatt","year":"2013","unstructured":"Bhatt S, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504\u20137.","journal-title":"Nature"},{"key":"2459_CR31","unstructured":"World Health Organization. Dengue and severe dengue. 2023 23\/08\/2023]; https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dengue-and-severe-dengue"},{"key":"2459_CR32","doi-asserted-by":"crossref","unstructured":"John S. A.L., Adaptive immune responses to primary and secondary dengue virus infections. Nat Rev Immunol 2019 19:4, 2019. 19(4).","DOI":"10.1038\/s41577-019-0123-x"},{"issue":"Pt 12","key":"2459_CR33","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1099\/vir.0.031641-0","volume":"92","author":"KL Mansfield","year":"2011","unstructured":"Mansfield KL, et al. Flavivirus-induced antibody cross-reactivity. J Gen Virol. 2011;92(Pt 12):2821\u20139.","journal-title":"J Gen Virol"},{"key":"2459_CR34","first-page":"334","volume":"11","author":"APS Rathore","year":"2020","unstructured":"Rathore APS, St John AL. Cross-Reactive Immun among Flaviviruses Front Immunol. 2020;11:334.","journal-title":"Cross-Reactive Immun among Flaviviruses Front Immunol"},{"issue":"9","key":"2459_CR35","doi-asserted-by":"publisher","first-page":"e0257182","DOI":"10.1371\/journal.pone.0257182","volume":"16","author":"U Limothai","year":"2021","unstructured":"Limothai U, et al. Dengue pre-vaccination screening test evaluation for the use of dengue vaccine in an endemic area. PLoS ONE. 2021;16(9):e0257182.","journal-title":"PLoS ONE"},{"issue":"6","key":"2459_CR36","doi-asserted-by":"publisher","first-page":"e427","DOI":"10.1016\/S2666-5247(22)00033-7","volume":"3","author":"SJ Savarino","year":"2022","unstructured":"Savarino SJ, et al. Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with a new dengue rapid diagnostic test: a retrospective analysis of phase 3 efficacy trials. Lancet Microbe. 2022;3(6):e427\u201334.","journal-title":"Lancet Microbe"},{"issue":"2","key":"2459_CR37","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jviromet.2011.02.013","volume":"173","author":"Y Fang","year":"2011","unstructured":"Fang Y, et al. Real-time monitoring of flavivirus induced cytopathogenesis using cell electric impedance technology. J Virol Methods. 2011;173(2):251\u20138.","journal-title":"J Virol Methods"},{"issue":"1","key":"2459_CR38","first-page":"1","volume":"2013 10","author":"N Canakoglu","year":"2013","unstructured":"Canakoglu N, et al. Pseudo-plaque reduction neutralization test (PPRNT) for the measurement of neutralizing antibodies to Crimean-Congo hemorrhagic fever virus. Virol J. 2013;2013 10(1):1.","journal-title":"Virol J"},{"issue":"2","key":"2459_CR39","doi-asserted-by":"publisher","first-page":"e31965","DOI":"10.1371\/journal.pone.0031965","volume":"7","author":"D Tian","year":"2012","unstructured":"Tian D, et al. Novel, real-time cell analysis for measuring viral cytopathogenesis and the efficacy of neutralizing antibodies to the 2009 influenza A (H1N1) virus. PLoS ONE. 2012;7(2):e31965.","journal-title":"PLoS ONE"},{"issue":"2","key":"2459_CR40","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.jviromet.2013.06.034","volume":"193","author":"Z Teng","year":"2013","unstructured":"Teng Z, et al. Real-time cell analysis\u2013a new method for dynamic, quantitative measurement of infectious viruses and antiserum neutralizing activity. J Virol Methods. 2013;193(2):364\u201370.","journal-title":"J Virol Methods"},{"issue":"2","key":"2459_CR41","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00430-017-0493-2","volume":"206","author":"JA M\u00fcller","year":"2017","unstructured":"M\u00fcller JA, et al. Development of a high-throughput colorimetric Zika virus infection assay. Med Microbiol Immunol. 2017;206(2):175\u201385.","journal-title":"Med Microbiol Immunol"},{"issue":"5","key":"2459_CR42","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/s41564-019-0399-4","volume":"4","author":"YX Setoh","year":"2019","unstructured":"Setoh YX, et al. Determinants of Zika virus host tropism uncovered by deep mutational scanning. Nat Microbiol. 2019;4(5):876\u201387.","journal-title":"Nat Microbiol"},{"key":"2459_CR43","doi-asserted-by":"publisher","first-page":"625136","DOI":"10.3389\/fmicb.2021.625136","volume":"12","author":"AA Amarilla","year":"2021","unstructured":"Amarilla AA, et al. An optimized high-throughput Immuno-Plaque assay for SARS-CoV-2. Front Microbiol. 2021;12:625136.","journal-title":"Front Microbiol"},{"issue":"1\u20132","key":"2459_CR44","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1\u20132):55\u201363.","journal-title":"J Immunol Methods"},{"key":"2459_CR45","doi-asserted-by":"crossref","unstructured":"Yenamandra SP et al. Evolution, heterogeneity and global dispersal of cosmopolitan genotype of Dengue virus type 2. Sci Rep, 2021. 11(1).","DOI":"10.1038\/s41598-021-92783-y"},{"issue":"2","key":"2459_CR46","doi-asserted-by":"publisher","first-page":"101387","DOI":"10.1016\/j.xpro.2022.101387","volume":"3","author":"N Suryadevara","year":"2022","unstructured":"Suryadevara N, et al. Real-time cell analysis: a high-throughput approach for testing SARS-CoV-2 antibody neutralization and escape. STAR Protoc. 2022;3(2):101387.","journal-title":"STAR Protoc"},{"key":"2459_CR47","unstructured":"AAT Bioquest Inc. Four Parameter Logistic (4PL) Curve Calculator. 2023 2023-12-11; https:\/\/www.aatbio.com\/tools\/four-parameter-logistic-4pl-curve-regression-online-calculator"},{"key":"2459_CR48","doi-asserted-by":"crossref","unstructured":"Schober P, Boer C, Schwarte LA. Correlation coefficients: appropriate use and interpretation. Volume 126. Anesthesia & Analgesia; 2018. 5.","DOI":"10.1213\/ANE.0000000000002864"},{"issue":"1","key":"2459_CR49","doi-asserted-by":"publisher","first-page":"204","DOI":"10.4269\/ajtmh.17-0819","volume":"99","author":"J Rajarethinam","year":"2018","unstructured":"Rajarethinam J, et al. Dengue in Singapore from 2004 to 2016: cyclical epidemic patterns dominated by serotypes 1 and 2. Am J Trop Med Hyg. 2018;99(1):204\u201310.","journal-title":"Am J Trop Med Hyg"},{"issue":"12","key":"2459_CR50","doi-asserted-by":"publisher","first-page":"16785","DOI":"10.3390\/ijms131216785","volume":"13","author":"J Johari","year":"2012","unstructured":"Johari J, et al. Antiviral activity of baicalein and quercetin against the Japanese encephalitis virus. Int J Mol Sci. 2012;13(12):16785\u201395.","journal-title":"Int J Mol Sci"},{"key":"2459_CR51","doi-asserted-by":"crossref","unstructured":"Mar\u00edn-Palma D et al. Curcumin inhibits in Vitro SARS-CoV-2 infection in Vero E6 cells through multiple antiviral mechanisms. Molecules, 2021. 26(22).","DOI":"10.3390\/molecules26226900"},{"issue":"7","key":"2459_CR52","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1002\/jmv.26917","volume":"93","author":"E Van Damme","year":"2021","unstructured":"Van Damme E, et al. In vitro activity of itraconazole against SARS-CoV-2. J Med Virol. 2021;93(7):4454\u201360.","journal-title":"J Med Virol"},{"key":"2459_CR53","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jviromet.2017.11.002","volume":"252","author":"C Charretier","year":"2018","unstructured":"Charretier C, et al. Robust real-time cell analysis method for determining viral infectious titers during development of a viral vaccine production process. J Virol Methods. 2018;252:57\u201364.","journal-title":"J Virol Methods"},{"key":"2459_CR54","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3389\/fcimb.2018.00335","volume":"8","author":"S Lebourgeois","year":"2018","unstructured":"Lebourgeois S, et al. Development of a real-time cell analysis (RTCA) method as a fast and accurate method for detecting infectious particles of the adapted strain of Hepatitis A Virus. Front Cell Infect Microbiol. 2018;8:335.","journal-title":"Front Cell Infect Microbiol"},{"key":"2459_CR55","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1186\/s13071-015-1104-y","volume":"8","author":"S Marlina","year":"2015","unstructured":"Marlina S, et al. Development of a real-time cell analysing (RTCA) method as a fast and accurate screen for the selection of Chikungunya virus replication inhibitors. Parasit Vectors. 2015;8:579.","journal-title":"Parasit Vectors"},{"key":"2459_CR56","doi-asserted-by":"publisher","first-page":"22791","DOI":"10.1038\/srep22791","volume":"6","author":"D Watterson","year":"2016","unstructured":"Watterson D, et al. A generic screening platform for inhibitors of virus induced cell fusion using cellular electrical impedance. Sci Rep. 2016;6:22791.","journal-title":"Sci Rep"},{"issue":"8","key":"2459_CR57","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1128\/JCM.03274-15","volume":"54","author":"J Piret","year":"2016","unstructured":"Piret J, Goyette N, Boivin G. Novel method based on real-time cell analysis for drug susceptibility testing of herpes Simplex Virus and Human Cytomegalovirus. J Clin Microbiol. 2016;54(8):2120\u20137.","journal-title":"J Clin Microbiol"},{"issue":"5","key":"2459_CR58","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1177\/1087057103256465","volume":"8","author":"BK Lundholt","year":"2003","unstructured":"Lundholt BK, Scudder KM, Pagliaro L. A simple technique for reducing edge effect in cell-based assays. J Biomol Screen. 2003;8(5):566\u201370.","journal-title":"J Biomol Screen"},{"issue":"11","key":"2459_CR59","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s10529-005-5803-x","volume":"27","author":"MI Patel","year":"2005","unstructured":"Patel MI, Tuckerman R, Dong Q. A pitfall of the 3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethonyphenol)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay due to evaporation in wells on the edge of a 96 well plate. Biotechnol Lett. 2005;27(11):805\u20138.","journal-title":"Biotechnol Lett"},{"key":"2459_CR60","first-page":"100987","volume":"26","author":"M Mansoury","year":"2021","unstructured":"Mansoury M, et al. The edge effect: a global problem. The trouble with culturing cells in 96-well plates. Biochem Biophys Rep. 2021;26:100987.","journal-title":"Biochem Biophys Rep"},{"issue":"1","key":"2459_CR61","doi-asserted-by":"publisher","first-page":"11130","DOI":"10.1038\/s41598-017-10415-w","volume":"7","author":"N Jaberolansar","year":"2017","unstructured":"Jaberolansar N, et al. Induction of high titered, non-neutralising antibodies by self-adjuvanting peptide epitopes derived from the respiratory syncytial virus fusion protein. Sci Rep. 2017;7(1):11130.","journal-title":"Sci Rep"},{"issue":"1","key":"2459_CR62","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.str.2017.11.017","volume":"26","author":"J Li","year":"2018","unstructured":"Li J, et al. Structural and functional characterization of a Cross-reactive Dengue Virus neutralizing antibody that recognizes a cryptic epitope. Structure. 2018;26(1):51\u2013e594.","journal-title":"Structure"},{"issue":"1","key":"2459_CR63","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1016\/S2214-109X(20)30392-2","volume":"9","author":"AL Lopez","year":"2021","unstructured":"Lopez AL, et al. Determining dengue virus serostatus by indirect IgG ELISA compared with focus reduction neutralisation test in children in Cebu, Philippines: a prospective population-based study. Lancet Glob Health. 2021;9(1):e44\u201351.","journal-title":"Lancet Glob Health"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-024-02459-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-024-02459-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-024-02459-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T14:08:20Z","timestamp":1725372500000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-024-02459-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2459"],"URL":"https:\/\/doi.org\/10.1186\/s12985-024-02459-y","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,3]]},"assertion":[{"value":"11 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was sought from the National Healthcare Group Domain Specific Review Board (NHG DSRB 2021\/00257) and Bioethics Review Committee of National Environment Agency\/Environmental Health Institute (NEA\/EHI\/IRB022). Blood donors provided written informed consent to test the samples for infectious diseases as part of the Donor Health Assessment Questionnaire Form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"208"}}